The University of Chicago Header Logo

Connection

Mark J. Ratain to Colorectal Neoplasms

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Colorectal Neoplasms.
Mark J. Ratain
Connection Strength
1.147
Colorectal Neoplasms
  1. Time to tumor growth: a model end point and new metric system for oncology clinical trials. J Clin Oncol. 2013 Jun 10; 31(17):2070-2.
    View in: PubMed
    Score: 0.263
  2. Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? J Clin Oncol. 2002 Jan 01; 20(1):7-8.
    View in: PubMed
    Score: 0.120
  3. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2021 01 01; 27(1):267-275.
    View in: PubMed
    Score: 0.110
  4. Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep. 2018 11 05; 8(1):16332.
    View in: PubMed
    Score: 0.096
  5. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Med. 2018 11; 7(11):5478-5487.
    View in: PubMed
    Score: 0.096
  6. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res. 2013 Dec 01; 19(23):6430-7.
    View in: PubMed
    Score: 0.068
  7. A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection. PLoS One. 2013; 8(5):e62989.
    View in: PubMed
    Score: 0.066
  8. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
    View in: PubMed
    Score: 0.057
  9. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009 Jun 01; 27(16):2604-14.
    View in: PubMed
    Score: 0.049
  10. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006 Dec; 7(8):1211-21.
    View in: PubMed
    Score: 0.042
  11. Phase II oncology trials: let's be positive. Clin Cancer Res. 2005 Aug 15; 11(16):5661-2.
    View in: PubMed
    Score: 0.038
  12. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005 Oct; 56(4):421-6.
    View in: PubMed
    Score: 0.038
  13. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2004 Apr 15; 22(8):1439-46.
    View in: PubMed
    Score: 0.035
  14. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
    View in: PubMed
    Score: 0.030
  15. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34.
    View in: PubMed
    Score: 0.023
  16. A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer. 1994 Jul 01; 74(1):168-73.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.